ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1194

Treatment Effect of Lorecivivint Across Multiple Trials in Patients with Knee OA: A Meta-analysis

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 1119

Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1454

Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US

SpA Including PsA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 1523

Trend Analysis of Lupus Nephritis Flares, Mortality, and Disparities: 2016-2020

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 0998

Trends and Disparities in Cardiovascular Deaths in Systemic Lupus Erythematosus: A Population-Based Retrospective Study in the United States from 1999 to 2021

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1349

Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1497

Type I Interferon Status and Clinical Manifestations in a Large Cohort of Patients with Systemic Lupus Erythematosus

SLE – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1416

Ultrasound (US)-guided Core-needle Biopsy (CNB) of the Non-swollen Parotid Gland: A Feasible and Well-tolerated Technique for Diagnosing and Stratifying Sjögren’s Disease (SjD)

Sjögren's Syndrome – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1639

Ultrasound Fast-Track Giant Cell Arteritis Clinic Experience in the United States

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1193

Ultrasound-Guided Corticosteroid Injection versus Iontophoresis in Rhizarthrosis: A Prospective Comparative Multicentric Study

Osteoarthritis – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0893

Uncovering Common and Distinctive Molecular Profiles Between Early and Stablished Rheumatoid Arthritis Through Integrative Multi-omics Analysis and Its Association with Disease Status and Clinical Response

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1116

Understanding the Prevalence, In-Hospital Mortality and Readmission Rates Amongst Pulmonary vs Cardiac Sarcoidosis Patients: Insights from a Nationwide Registry

Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1284

Unlocking Insights into Juvenile Dermatomyositis: Clinical and Demographic Profiles Paired with Total Improvement Scores at a Tertiary Center

Pediatric Rheumatology – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 0889

Unraveling the Progression of Sjögren’s Disease at the Cellular and Histological Level Using Single-cell and Spatial Transcriptomics

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1620

Unveiling of a New Molecular Imaging Biomarker? Vascular Adhesion Protein-1 and [68Ga]Ga-DOTA-Siglec-9 PET/CT in Detecting Giant Cell Arteritis Relapse

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].